science wire

« BACK

Pharmacology



Results 1051 - 1100 of 1868.


Health - Pharmacology - 22.06.2017
ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis † Despite current treatments about 40% of heart attack survivors remain at increased risk of† recurrent heart attack, stroke or cardiovascular death because of hi

Pharmacology - Health - 21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o

Health - Pharmacology - 20.06.2017
Almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 patients , 42% of CU patients studied are not receiving any treatment for their debilitatin

Pharmacology - Health - 20.06.2017
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III†studies , † 57% and 52% of patients receiving RTH258 6 mg in the respective trials were maintained exclusively on a q12w interval immediately following the loading phase and continuing through week 48 , † In both studies overall ocular and non-ocular adverse event rates for RTH258

Health - Pharmacology - 19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.

Health - Pharmacology - 17.06.2017
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease ‚? These new data underscore the disconnect between self-perceived control and clinical reality; a potentially limiting factor in patients seeking support to better control their condition ‚? Helping patients recognize the possibilities of living a life with properly controlled asthma is central to a major new global p

Pharmacology - Health - 15.06.2017
Novartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx ‚? is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , ‚? Additional data show rapid and sustained pain relief with Cosentyx as early as Week 3 which is sustained out to 2 years in PsA patients ‚? Patient recruitment underway for the new EXCEED head-to-head clinical trial to show superiority of Cosentyx versus Humira ‚? * in PsA The di

Pharmacology - Health - 15.06.2017
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus‚?
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ‚? Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicin

Pharmacology - Health - 08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?

Health - Pharmacology - 07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi

Pharmacology - Health - 06.06.2017
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna in Ph+ CML-CP patients in both the first-line setting and after switching from Glivec ‚?

Pharmacology - Health - 05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub

Health - Pharmacology - 05.06.2017
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with IBM Watson Health proficiency in data analytics and machine learning Collaboration initiating in breast cancer given Novartis heritage and expertise; opportunity to expand to enhance outcomes for patients with other cancers ‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚' ‚?

Health - Pharmacology - 05.06.2017
Roche‚? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Roche‚??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms

Health - Pharmacology - 05.06.2017
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist ‚? (trametinib) in combination with Opdivo ‚? (nivolumab) and Opdivo + Yervoy ‚? (ipilimumab) ‚? Collaboration expands upon existing clinical investigation of Op

Health - Pharmacology - 04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o

Pharmacology - Health - 03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a

Health - Pharmacology - 02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent

Life Sciences - Pharmacology - 02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.

Health - Pharmacology - 31.05.2017
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process counters slow progress in developing new cryptosporidiosis treatments Scientists report discovery of Cryptosporidium PI(4)K inhibitor candidate KDU731 in new issue of Nature - Infectious disease scientists from Novartis, the University of Georgia and Washing

Pharmacology - Health - 31.05.2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Building depth across key therapeutic areas wi

Health - Pharmacology - 31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac

Health - Pharmacology - 31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.

Pharmacology - Health - 30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.

Pharmacology - Health - 26.05.2017
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy † The overall intracranial response r

Health - Pharmacology - 24.05.2017
New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in p

Health - Pharmacology - 23.05.2017
Novartis’ new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids
New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of white blood cell)† counts † Data was published in the centenary issue of the American Thoracic Society's 'American Journal of Respiratory and Critical Care Medicine' † Together with the International Primary Care Respiratory Group, Novartis is launching

Pharmacology - Health - 23.05.2017
FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis
FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra /RoActemra (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.

Health - Pharmacology - 19.05.2017
Novartis receives positive CHMP opinion for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases Zykadia is

Pharmacology - Health - 18.05.2017
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be presente

Health - Pharmacology - 11.05.2017
Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 20 Roche medicines are included in more than 190

Pharmacology - Health - 10.05.2017
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (

Health - Pharmacology - 04.05.2017
Comprehensive Atlas of Immune Cells in Renal Cancer
Comprehensive Atlas of Immune Cells in Renal Cancer
Renal cell carcinoma is one of the most frequent and deadly urogenital cancers. Even if the tumors are treated, they ultimately end in metastasis in about half of the patients. 90 percent of these patients die within five years. Thanks to new kinds of immunotherapies, the outlook of this patient group has improved, but the treatment only works for a minority of patients.

Pharmacology - Health - 04.05.2017
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH † Conatus has initiated the Phase IIb ENCORE-LF clinical trial with emricasan in NASH.

Pharmacology - Health - 28.04.2017
Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) Approval in newly diagnosed FLT3-mutated AML repre

Health - Pharmacology - 26.04.2017
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma Now available in the UK, G

Pharmacology - Economics / Business - 25.04.2017
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued Net sales grew 2% (cc, -1

Pharmacology - Health - 24.04.2017
Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS † Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined) and 38% achieved NEDA-4 (NEDA-3 plus no brain shrinkage), further supporting findings from clinic

Pharmacology - Health - 24.04.2017
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada Novartis and Amgen to co-commercialize AMG 334

Pharmacology - Health - 21.04.2017
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.

Pharmacology - Health - 21.04.2017
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials
The Bill & Melinda Gates foundation has†awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.

Health - Pharmacology - 20.04.2017
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia NIH study found 58% of patients with treatment-naÔve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy † The historical complete response rate was 10% for untreated patients with SAA on immunosup

Pharmacology - Health - 19.04.2017
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and

Health - Pharmacology - 18.04.2017
FDA grants Roche’s TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer
FDA grants Roche's TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder

Pharmacology - Health - 18.04.2017
FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat

Pharmacology - Health - 18.04.2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) † R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation † Advances in CTL019 result from collaboration with the University of Pennsylvania; regulatory submissions for r/r DLBCL are expected

Pharmacology - Health - 18.04.2017
Novartis expands development programs for NASH through clinical collaboration with Allergan
Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive† form of non-alcoholic fatty liver disease † There are currently no ap

Health - Pharmacology - 18.04.2017
Synthetic Carbohydrates against Autoimmune Diseases
Researchers are developing an innovative approach for the treatment of a rare autoimmune disease of the peripheral nervous system, using a type of molecular sponge consisting of carbohydrates to remove pathogenic antibodies from the bloodstream. Developed to treat anti-MAG neuropathy, the approach also has potential applications for the treatment of other autoimmune diseases.

Pharmacology - Health - 17.04.2017
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibi

Health - Pharmacology - 10.04.2017
Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment Data will be submitted to global

This site uses cookies and analysis tools to improve the usability of the site. More information. |